Amgen's Trading Volume Drops 38.88% to $776 Million Ranking 89th in Daily Volume

On May 5, 2025, Amgen's trading volume reached $776 million, marking a 38.88% decrease from the previous day. The stock ranked 89th in terms of trading volume for the day. Amgen's stock price fell by 0.41%, marking the third consecutive day of decline, with a total decrease of 3.73% over the past three days.

Amgen reported strong first-quarter 2025 results, driven by robust sales growth from its key drugs. Total product revenues increased by 11% year-over-year to $7.87 billion, despite continued price declines. The company's top-performing drugs, Repatha, Evenity, and Blincyto, significantly contributed to this growth. Repatha's sales surged by 27% to $656 million, while Evenity's sales grew by 29% to $442 million. Prolia also saw a 10% increase in sales.

Amgen's first-quarter earnings of $4.90 per share exceeded estimates of $4.16 per share, reflecting a 24% year-over-year increase. This strong performance was largely attributed to higher revenues, which were partially offset by price declines. The company's focus on key drugs has been instrumental in driving sales growth and exceeding market expectations.